Visiongain has launched a new pharma report “Single Cell Analysis Market Report 2020-2030” Prospects by Type {Consumables (Assay Kits, Reagents, Others), Instruments (Manually operated Instruments, Automated instruments)}, Application (Cancer, Immunology, Neurology, Stem cell, Non-invasive prenatal diagnosis, In-vitro fertilization), Cell type (Human Cells, Animal Cells, Microbial Cells), End use (Academic & Research Laboratories, Biotechnology and Pharmaceutical Companies, Diagnostic Laboratories, IVF Centers), and Geography.

Global single cell analysis market is projected to grow on account of rising prevalence of neurological disorders, growing focus on personalized medicine, wide applications of single cell analysis in cancer research, and increasing government funding for cell-based research among others are anticipated to propel market growth. The global market is projected to grow at a lucrative CAGR of ~18% and anticipated to surpass USD ~2 Billion by 2020.

Single-cell sequencing is an emerging technology that helps to sequence a single cell level of the entire human genome. It includes epigenomics, genomics, proteomics, transcriptomics, and metabolomics with increased sensitivity to a single-cell level. Throughout genomics, important roles are played by new generation methodologies like next-generation sequencing and third-generation sequencing. The goal of single-cell research is mainly to quantify and analyze the heterogeneity of cells.

Growth in this market is driven primarily by technological advances in single-cell analysis devices, increased government funding for cell-based research, increased biotechnology and biopharmaceutical industries, large applications of single-cell analysis in cancer research, increased focus on personalized medicine, and increased incidence and prevalence of chronic and infectious diseases.

More than 2,000 clinical trials are currently underway to determine the efficacy of single-cell testing in successful immunology treatment of different types of cancer and diseases, including Aids, hepatitis, and influenza. Likewise, major players are investing in R&D to test single-cell analysis technologies in stem cell transplant procedures to improve the success rates of these procedures. The advent of advanced devices that allow easy procedures for transcriptomics and proteomics cause the adoption of techniques for single-cell analysis.

However, the high cost of instruments is restricting market expansion. Demand for analytical tools and technical advances leads to high-end equipment being introduced. By using limited specimens, advances contribute to newly developed features such as high sensitivity, reliability, and efficacy. It is anticipated that these developments would increase overall instrument costs. Polymerase chain reaction (PCR)-based assays, stem cell therapies and other analyzes based on single cells entail high clinical costs due to the expenses of the instruments used. Therefore, high production costs are likely to hinder market growth in developing countries and lower-income nations.

North America dominated the global single-cell analysis market in 2018, followed by Europe. North America's supremacy has been due largely to the region's establishment of major biotechnology and biopharmaceutical firms. Also, the adoption of gene-based analytical techniques by these companies and research laboratories is fueling regional market growth.

The Asia Pacific is projected to witness the fastest growth over the forecast period as a result of numerous government measures to improve healthcare infrastructure, the availability of skilled professionals to operate with advanced analytical tools, and increasing healthcare spending. However, the emergence of a significantly large target population, increased demand for genetic analysis, and the booming medical tourism industry are likely to increase market growth further.

Some of the major players operating in this industry are Agilent Technologies, Beckman Coulter, Inc. (A Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Fluidigm Corporation, GE Healthcare, Illumina, Inc., Merck KGaA, Qiagen N.V., Thermo Fisher Scientific, Inc., Eppendorf AG, WaferGen Bio-Systems, Inc., NuGen Technologies, Inc., CELLDOM, Sphere Fluidics Limited, Celsee, Inc., IncellDx, Honeycomb Biotechnologies, Inc., and Takara Bio Inc., among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.